Fig. 1From: LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signalingLMO3 expression is upregulated in HCC and closely related with clinicopathological findings or patient prognoses. a The mRNA expression level of LMO3 in 16 cases HCC and 12 cases corresponding noncancerous liver (CNL) tissues. b The mRNA expression level of LMO3 in 12 paired HCC and CNL tissues. c The protein expression level of LMO3 in 5 paired HCC and CNL tissues. **Pā<ā0.01. d The immunohistochemical staining of LMO3 in HCC and CNL tissues. Scale bars: 10Ā Ī¼m. e By analyzing HCC tissue microarray (nā=ā180), the expression of LMO3 was found to be upregulated in 75.40% HCC tissues. f The immunohistochemical staining of LMO3 in HCC, thrombus, CNL and normal liver tissues. Scale bars: 5Ā Ī¼m. g Western blotting analysis of LMO3 expression in HCC, thrombus, CNL and normal liver tissues. GAPDH was used as a loading control. h and i Kaplan-Meier analysis of overall survival (OS) (f, Pā=ā0.019) and disease-free survival (DFS) (g, Pā=ā0.179) for the expression of LMO3Back to article page